Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-16T22:18:24.710Z Has data issue: false hasContentIssue false

Assessment of quality of life and cognitive dysfunction among patients with Major Depressive Disorder

Published online by Cambridge University Press:  19 July 2023

L. Abbasi*
Affiliation:
Faculty of Medicine, Al-Balqa Applied University, Salt
T. Mazzawi
Affiliation:
Faculty of Medicine, Al-Balqa Applied University, Salt
T. Daradkeh
Affiliation:
Jordan University of Science and Technology, Irbid, Jordan
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Major Depressive Disorder (MDD) is associated with high mortality, disability and morbidity. Studies demonstrated mixed results on effects of depression treatments on quality of life (QOL).

Objectives

To evaluate the severity of depression among Jordanian patients diagnosed with MDD before and after treatment and to find any relationship between QOL, depression severity and perceived cognitive dysfunction.

Methods

Patients from both genders, 18-65 years old and diagnosed with MDD were included to attend two visits; at baseline and 6 weeks after treatment, in each they completed three questionnaires: Patient Health Questionnaire (PHQ-9) for depression severity, patient-rated Perceived Deficit Questionnaire (PDQ-5) for cognitive function, and World Health Organization Quality of Life Brief (WHOQOL-BREF) format.

Results

A total of 92 patients completed the study. The scores of the different questionnaires and their correlations before and after treatment are presented in tables 1 and 2. Correlations between PHQ-9 and PDQ-5 before and after treatment are illustrated in figs 1 and 2, respectively.Table 1:

Total scores for WHOQOL-BREF format, PDQ-5 and PHQ-9, before and after treatment

QuestionnaireBeforeAfterP-value
General quality of life2.5±13.5±0.7<0.0001
General health satisfaction2.3±13.4±0.9<0.0001
Physical health (Domain 1)10±2.613.9±2.6<0.0001
Psychological (Domain 2)8±2.312.6±2.3<0.0001
Social relationships (Domain 3)9±3.212.8±2.8<0.0001
Environment (Domain 4)12.3±314.4±7.50.0003
Patient-rated Perceived Deficit 5 (PDQ-5)13±4.47.2±4<0.0001
Patient health questionnaire 9 (PHQ-9)19±5.47.1±5.1<0.0001

Values are presented as mean±SD. Analysis: Paired t test. P<0.05 is significant.

Table 2:

Correlations between total scores for all of the domains for WHOQOL-BREF and PDQ-5, and between WHOQOL-BREF and PHQ-9, before and after treatment

Domains/FacetsPatient-rated Perceived Deficit 5 (PDQ-5)Patient health questionnaire 9 (PHQ-9)
Before (r, p)After (r, p)Before (r, p)After (r, p)
General quality of life-0.38, 0.0001-0.26, 0.01-0.55, <0.0001-0.49, <0.0001
General health satisfaction-0.24, 0.02-0.14, 0.2-0.51, <0.0001-0.48, <0.0001
Physical health (Domain 1)-0.37, 0.0003-0.50, <0.0001-0.57, <0.0001-0.76, <0.0001
Psychological (Domain 2)-0.46, <0.0001-0.43, <0.0001-0.58, <0.0001-0.68, <0.0001
Social relationships (Domain 3-0.37, 0.0002-0.37, 0.0002-0.42, <0.0001-0.40, <0.0001
Environment (Domain 4)-0.52, <0.0001-0.21, 0.047-0.36, 0.0004-0.12, 0.2

Spearman correlation (r); P<0.05 is significant. WHOQOL: World Health Organization Quality of Life.

Image:

Image 2:

Conclusions

Significant improvements were found in the symptoms of depression, cognition and QOL in patients with MDD after treatment. Depression severity significantly inversely correlated with QOL and cognition of MDD patients.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.